Daewoong Pharmaceutical

Daewoong Pharmaceutical plans to invest 100 billion won ($74.6 million) to build a third botulinum toxin production facility in Hwaseong, Gyeonggi Province, South Korea. Construction is expected to start in H1 2023 and be completed by 2024, adding capacity for up to 18 million vials per year.